GLP-1R agonists demonstrate potential to treat Wolfram syndrome in human preclinical models

Abstract

Our study provides novel evidence for the beneficial effect of GLP-1R agonists on WFS1-deficient human pancreatic beta cells and neurons, suggesting that these drugs may be considered as a treatment for individuals with Wolfram syndrome.